Novartis Ag Share Price Today
(NASDAQ: NVS)

Name: Novartis Ag Share Price Today (NASDAQ: NVS) - Novartis Ag Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Novartis Ag share price is $111.88 & ₹9,730.09 as on 6 Mar 2025, 2.30 'hrs' IST

$111.88

▲

0.46

(0.41%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Novartis Ag share price in Dollar and Rupees. Guide to invest in Novartis Ag stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Novartis Ag, along with analyst recommendations, forecasts, and comprehensive financials.

Novartis Ag share price movements

Today's Low: $111.86
Today's High: $112.77
$111.88
0.02%
Downside
Day's Volatility :0.81%
Upside
0.79%
52 Weeks Low: $92.35
52 Weeks High: $120.92
$111.88
17.46%
Downside
52 Weeks Volatility :23.63%
Upside
7.48%

Novartis Ag (NVS) Returns

Period	Novartis Ag	Sector (Health Care)	Index (Russel 2000)
3 Months	9.13%	2.7%	0.0%
6 Months	-4.35%	-3.7%	0.0%
1 Year	9.0%	1.5%	0.0%
3 Years	33.37%	11.8%	-11.6%

Novartis Ag (NVS) Key Statistics

in dollars & INR

Previous Close	$111.42
Open	$112.02
Today's High	$112.77
Today's Low	$111.86
Market Capitalization	$218.5B
Today's Volume	$502.5K
52 Week High	$120.92
52 Week Low	$92.35
Revenue TTM	$51.7B
EBITDA	$20.7B
Earnings Per Share (EPS)	$5.87
PE Ratio	18.85
Dividend Yield	3.55%
Profit Margin	23.09%
Quarterly Earnings Growth YOY	-0.66%
Return On Equity TTM	26.28%

How to invest in Novartis Ag Stock (NVS) from India?

It is very easy for Indian residents to invest directly in Novartis Ag from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Novartis Ag stock in both Indian Rupees (INR) and US Dollars (USD). Search for Novartis Ag or NVS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Novartis Ag or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Novartis Ag shares which would translate to 0.008 fractional shares of Novartis Ag as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Novartis Ag, in just a few clicks!

Returns in Novartis Ag (NVS) for Indian investors in Rupees

The Novartis Ag stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Novartis Ag investment value today

Current value as on today

₹1,13,951

Returns

₹13,951

(+13.95%)

Returns from Novartis Ag Stock

₹9,002 (+9%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Novartis Ag (NVS)

-10.75%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Investment in Novartis Ag Shares from India has dropped by -10.75% over the past 30 days, indicating reduced transactional activity.

-24%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Novartis Ag Stock from India on INDmoney has decreased by -24% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Novartis Ag

Dodge & Cox
0.62%
PRIMECAP Management Company
0.56%
Dimensional Fund Advisors, Inc.
0.41%
Morgan Stanley - Brokerage Accounts
0.35%
Loomis, Sayles & Company LP
0.28%
Bank of America Corp
0.23%

Analyst Recommendation on Novartis Ag

Buy

50%Buy

43%Hold

6%Sell

Based on 32 Wall street analysts offering stock ratings for Novartis Ag(by analysts ranked 0 to 5 stars)

Based on 32 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Novartis Ag Stock (NVS)

What analysts predicted

Downside of 1.73%

Target:

$109.94

Current:

$111.88

Insights on Novartis Ag Stock (Ticker Symbol: NVS)

Price Movement
In the last 7 days, NVS stock has moved up by 2.3%
Increasing Revenue
Novartis AG has shown consistent revenue growth over the last five quarters. Revenue increased from $11.77 billion to $13.55 billion, with an average increase of 3.4% each quarter.
Decreasing Net Profit
Novartis AG's net profit has been declining for the last three quarters. It decreased from $3.24 billion to $2.81 billion, resulting in an average decrease of 6.7% each quarter.
NVS vs LLY (1 yr)
In the last 1 year, Eli Lilly And Company has given 16.8% return, outperforming this stock by 8.2%
NVS vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 246.6% return, outperforming this stock by 215.1%
Price to Sales
Novartis AG has a Price-to-Sales (P/S) ratio of 4.4, meaning that investors are willing to pay $4.4 for every $1 of sales the company generates. In comparison, Eli Lilly and Company has a significantly higher P/S ratio of 18.6, indicating that investors are paying $18.6 for every $1 of sales from that company. This suggests that investors view Eli Lilly's sales as having greater value relative to Novartis's sales.

NVS Novartis Ag Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$48.7B	↓ 8.44%
Net Income	$7.1B	↓ 43.33%
Net Profit Margin	14.68%	↓ 9.04%

	FY20	Y/Y Change
Revenue	$49.9B	↑ 2.51%
Net Income	$8.1B	↑ 12.94%
Net Profit Margin	16.18%	↑ 1.5%

	FY21	Y/Y Change
Revenue	$52.9B	↑ 5.97%
Net Income	$24.0B	↑ 197.58%
Net Profit Margin	45.43%	↑ 29.25%

	FY22	Y/Y Change
Revenue	$51.8B	↓ 1.98%
Net Income	$7.0B	↓ 71.05%
Net Profit Margin	13.42%	↓ 32.01%

	FY23	Y/Y Change
Revenue	$46.7B	↓ 9.97%
Net Income	$14.9B	↑ 113.52%
Net Profit Margin	31.83%	↑ 18.41%

	FY24	Y/Y Change
Revenue	$51.7B	↑ 10.85%
Net Income	$11.9B	↓ 19.59%
Net Profit Margin	23.09%	↓ 8.74%

	Q3 FY23	Q/Q Change
Revenue	$12.1B	↓ 13.23%
Net Income	$1.8B	↓ 23.96%
Net Profit Margin	14.56%	↓ 2.06%

	Q4 FY23	Q/Q Change
Revenue	$11.8B	↓ 2.61%
Net Income	$8.5B	↑ 381.54%
Net Profit Margin	72.01%	↑ 57.45%

	Q1 FY24	Q/Q Change
Revenue	$11.8B	↑ 0.45%
Net Income	$2.7B	↓ 68.3%
Net Profit Margin	22.72%	↓ 49.29%

	Q2 FY24	Q/Q Change
Revenue	$12.5B	↑ 5.77%
Net Income	$3.2B	↑ 20.76%
Net Profit Margin	25.94%	↑ 3.22%

	Q3 FY24	Q/Q Change
Revenue	$13.2B	↑ 5.27%
Net Income	$3.2B	↓ 1.76%
Net Profit Margin	24.21%	↓ 1.73%

	Q4 FY24	Q/Q Change
Revenue	$13.6B	↑ 2.93%
Net Income	$2.8B	↓ 11.63%
Net Profit Margin	20.78%	↓ 3.43%

	FY19	Y/Y Change
Profit	$34.3B	↓ 1.46%

	FY20	Y/Y Change
Profit	$34.8B	↑ 1.53%

	FY21	Y/Y Change
Profit	$37.0B	↑ 6.42%

	FY22	Y/Y Change
Profit	$36.3B	↓ 1.8%

	FY23	Y/Y Change
Profit	$34.2B	↓ 5.93%

	FY24	Y/Y Change
Profit	$38.9B	↑ 13.77%

	Q3 FY23	Q/Q Change
Profit	$9.0B	↓ 6.46%

	Q4 FY23	Q/Q Change
Profit	$8.8B	↓ 2.46%

	Q1 FY24	Q/Q Change
Profit	$8.7B	↓ 0.63%

	Q2 FY24	Q/Q Change
Profit	$9.3B	↑ 6.85%

	Q3 FY24	Q/Q Change
Profit	$9.9B	↑ 6.92%

	Q4 FY24	Q/Q Change
Profit	$10.2B	↑ 2.98%

	FY19	Y/Y Change
Operating Cash Flow	$13.6B	↓ 4.53%
Investing Cash Flow	$-2.2B	↓ 60.19%
Financing Cash Flow	$-13.6B	↑ 221.09%

	FY20	Y/Y Change
Operating Cash Flow	$13.7B	↑ 0.18%
Investing Cash Flow	$-13.2B	↑ 492.18%
Financing Cash Flow	$-2.2B	↓ 83.8%

	FY21	Y/Y Change
Operating Cash Flow	$15.1B	↑ 10.41%
Investing Cash Flow	$4.2B	↓ 131.92%
Financing Cash Flow	$-16.3B	↑ 636.59%

	FY22	Y/Y Change
Operating Cash Flow	$14.2B	↓ 5.54%
Investing Cash Flow	$1.5B	↓ 65.11%
Financing Cash Flow	$-20.6B	↑ 26.43%

	FY23	Y/Y Change
Operating Cash Flow	$14.5B	↑ 1.56%
Investing Cash Flow	$5.6B	↑ 281.2%
Financing Cash Flow	$-14.3B	↓ 30.56%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$5.4B	↑ 50.39%
Investing Cash Flow	$-2.2B	↑ 110.07%
Financing Cash Flow	$-832.0M	↓ 77.12%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$2.5B	↓ 52.64%
Investing Cash Flow	$-1.8B	↓ 20.43%
Financing Cash Flow	$-607.0M	↓ 27.04%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$2.3B	↓ 11.07%
Investing Cash Flow	$-899.0M	↓ 48.92%
Financing Cash Flow	$-5.2B	↑ 750.74%

Novartis Ag Technicals Summary

Sell

Neutral

Buy

Novartis Ag is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Novartis Ag (NVS) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Novartis Ag	6.08%	-4.35%	9.0%	33.37%	37.34%
Eli Lilly And Company	10.29%	-0.19%	16.84%	248.21%	571.28%
Johnson & Johnson	7.77%	0.26%	3.82%	-3.94%	21.24%
Merck & Co. Inc.	2.7%	-21.42%	-24.69%	19.89%	18.02%
Novo Nordisk A/s	5.91%	-33.15%	-29.86%	73.53%	194.37%
Abbvie Inc	11.37%	9.69%	16.83%	41.55%	148.08%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Novartis Ag	18.85	18.85	3.26	8.45	0.26	0.1	0.04	22.3
Eli Lilly And Company	79.36	79.36	1.37	23.09	0.84	0.15	0.01	15.81
Johnson & Johnson	28.89	28.89	1.12	10.57	0.2	0.08	0.03	29.7
Merck & Co. Inc.	13.82	13.82	0.07	8.98	0.41	0.14	0.04	18.32
Novo Nordisk A/s	28.1	28.1	1.44	0.0	0.81	0.22	0.02	32.31
Abbvie Inc	88.86	88.86	0.44	12.27	0.62	0.08	0.03	1.88

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Novartis Ag	Buy	$218.5B	37.34%	18.85	23.09%
Eli Lilly And Company	Buy	$818.3B	571.28%	79.36	23.51%
Johnson & Johnson	Buy	$402.7B	21.24%	28.89	15.84%
Merck & Co. Inc.	Buy	$235.3B	18.02%	13.82	26.67%
Novo Nordisk A/s	Buy	$393.1B	194.37%	28.1	34.78%
Abbvie Inc	Buy	$373.3B	148.08%	88.86	7.59%

Novartis Ag Dividend announcements

Novartis Ag Dividends March, 2025
In the quarter ending March,2025. Novartis Ag has declared dividend of $3.87

About Novartis Ag

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Organization	Novartis Ag
Employees	75883
CEO	Dr. Vasant Narasimhan M.D.
Industry	Health Technology

Management People of Novartis Ag

Name	Title
Dr. Vasant Narasimhan M.D.	Chief Executive Officer
Mr. Harry Kirsch	Chief Financial Officer
Mr. Victor Bulto	President of US
Dr. Patrick Horber M.D.	President of International
Dr. Steffen Lang Ph.D.	President of Operations
Paul Penepent	Head of Group Financial Reporting and Accounting
Ms. Sloan Simpson	Global Head of Investor Relations
Dr. Klaus Moosmayer Ph.D.	Chief Ethics, Risk & Compliance Officer
Ms. Karen L. Hale	Chief Legal Officer
Dr. Robert Kowalski Pharm.D.	Chief People & Organization Officer

Important FAQs about investing in NVS Stock from India :

What is Novartis Ag share price today?

Novartis Ag share price today stands at $111.88, Open: $112.02 ; Previous Close: $111.42 ; High: $112.77 ; Low: $111.86 ; 52 Week High: $120.92 ; 52 Week Low: $92.35.

The stock opens at $112.02, after a previous close of $111.42. The stock reached a daily high of $112.77 and a low of $111.86, with a 52-week high of $120.92 and a 52-week low of $92.35.

Can Indians buy Novartis Ag shares?

Yes, Indians can invest in the Novartis Ag (NVS) from India.

With INDmoney, you can buy Novartis Ag at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Novartis Ag at zero transaction cost.

How can I buy Novartis Ag shares from India?

It is very easy to buy Novartis Ag from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Novartis Ag (NVS) be purchased?

Yes, you can buy fractional shares of Novartis Ag with INDmoney app.

What are the documents required to start investing in Novartis Ag stocks?

To start investing in Novartis Ag, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.